Infrequent tacrolimus-induced nephrotoxicity in French patients with steroid-dependent nephrotic syndrome

Pediatr Nephrol. 2019 Dec;34(12):2605-2608. doi: 10.1007/s00467-019-04343-2. Epub 2019 Sep 13.

Abstract

Background: Chronic nephrotoxicity with potentially irreversible lesions is a major concern regarding calcineurin inhibitor (CNI) treatment in children with severe forms of idiopathic nephrotic syndrome (INS).

Case-diagnosis/treatment: We retrospectively included all children on CNI for steroid-dependent INS with a duration of CNI treatment of more than 1 year. Only patients in whom CNI could not be replaced by mycophenolate mofetil were included. All included patients underwent a kidney biopsy. All results were expressed as median and range. Twenty-one children (6 girls) were included. Age at disease onset was 49 (29-66) months and treatment duration on CNI was 30 (20-45) months. Age at kidney biopsy was 108 (78-170) months. Number of relapses was 7 (3-9) since disease onset. Serum creatinine level was transiently and moderately increased in two patients. Kidney biopsy revealed minimal change disease in 20/21 patients and focal segmental glomerulosclerosis in 1/21. Evidence for chronic CNI nephrotoxicity was found in one patient revealed by arteriolar hyalinosis and fibrosis in 50% of glomeruli.

Conclusions: CNI-induced chronic nephrotoxicity was infrequent. In patients who require long-term and/or high-dose CNI treatment, kidney biopsies might be useful to exclude chronic CNI-induced lesions.

Keywords: Children; Cyclosporine; Idiopathic nephrotic syndrome; Nephrotoxicity; Tacrolimus.

Publication types

  • Observational Study

MeSH terms

  • Child, Preschool
  • Female
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / adverse effects*
  • Male
  • Nephrotic Syndrome / drug therapy*
  • Renal Insufficiency, Chronic / chemically induced*
  • Retrospective Studies
  • Tacrolimus / administration & dosage
  • Tacrolimus / adverse effects*

Substances

  • Immunosuppressive Agents
  • Tacrolimus